High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

PubWeight™: 4.60‹?› | Rank: Top 1%

🔗 View Article (PMID 10856105)

Published in J Clin Oncol on June 01, 2000

Authors

J M Kirkwood1, J G Ibrahim, V K Sondak, J Richards, L E Flaherty, M S Ernstoff, T J Smith, U Rao, M Steele, R H Blum

Author Affiliations

1: Department of Pathology, University of Pittsburgh Medical Center, PA 15213-2582, USA. jmk@jimmy.harvard.edu

Articles citing this

(truncated to the top 100)

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol (2010) 2.41

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Missing data in clinical studies: issues and methods. J Clin Oncol (2012) 2.05

Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol (2012) 1.40

Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol (2003) 1.36

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34

A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther (2010) 1.30

Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28

Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26

Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis. J Gastroenterol (2011) 1.26

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22

Flexible Cure Rate Modeling Under Latent Activation Schemes. J Am Stat Assoc (2007) 1.20

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest (2003) 1.17

Function and regulation of retinoic acid-inducible gene-I. Crit Rev Immunol (2010) 1.15

Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12

IFN-α in the treatment of melanoma. J Immunol (2012) 1.12

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg (2002) 1.11

Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications. J Drug Deliv (2012) 1.10

Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10

Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res (2012) 1.10

Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.09

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol (2014) 1.07

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02

Adjuvant therapy for melanoma. Cancer J (2012) 1.01

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist (2012) 1.01

A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res (2009) 1.01

Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01

Statistical issues and challenges in immuno-oncology. J Immunother Cancer (2013) 0.99

Bayesian case influence diagnostics for survival models. Biometrics (2008) 0.96

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93

Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer (2011) 0.91

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91

Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol (2011) 0.90

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol (2016) 0.89

Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89

Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 0.88

Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol (2010) 0.88

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88

The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87

Cutaneous Melanoma in Asians. Chonnam Med J (2016) 0.86

Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ (2006) 0.84

Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol (2008) 0.84

Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS One (2012) 0.84

A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother (2014) 0.84

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer (2001) 0.84

Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83

Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study. Melanoma Res (2011) 0.83

Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res (2014) 0.82

Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw (2013) 0.81

Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690. BMC Med Res Methodol (2012) 0.81

Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol (2013) 0.81

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. BMC Cancer (2006) 0.81

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80

Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. Cancer Med (2015) 0.80

Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer (2008) 0.80

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med (2015) 0.80

Thick primary melanoma has a heterogeneous tumor biology: an institutional series. World J Surg Oncol (2011) 0.80

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. J Immunol Res (2016) 0.80

The power prior: theory and applications. Stat Med (2015) 0.79

Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother (2014) 0.79

Cutaneous melanoma: new advances in treatment. An Bras Dermatol (2014) 0.79

[Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma]. Ophthalmologe (2006) 0.78

Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78

Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma. J Cancer Res Clin Oncol (2010) 0.78

Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics (2009) 0.78

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol (2015) 0.78

SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol (2015) 0.77

Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol (2015) 0.77

Adjuvant therapy of melanoma: at what cost? J Clin Oncol (2001) 0.77

Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res (2011) 0.76

IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy (2016) 0.76

In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma. J Clin Immunol (2006) 0.76

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Ann Transl Med (2015) 0.76

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol (2008) 0.75

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer (2016) 0.75

A patient-centered methodology that improves the accuracy of prognostic predictions in cancer. PLoS One (2013) 0.75

Malignant melanoma (non-metastatic). BMJ Clin Evid (2007) 0.75

Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma. PLoS One (2016) 0.75

The use of immunotherapy in the treatment of melanoma. J Hematol Oncol (2017) 0.75

Treatment options for metastatic melanoma in solid organ transplant recipients. JAAD Case Rep (2015) 0.75

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. PLoS One (2014) 0.75

Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J (2014) 0.75

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma. Clinicoecon Outcomes Res (2015) 0.75

Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma. Curr Oncol (2010) 0.75

Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother (2016) 0.75

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer (2016) 0.75

Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma. Nat Clin Pract Oncol (2009) 0.75

Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J (2010) 0.75

Adjuvant interferon alfa for melanoma. Curr Oncol (2010) 0.75

Adjuvant pegylated interferon α-2b therapy for melanoma. Oncol Lett (2010) 0.75

Malignant melanoma of the penis and urethra: one case report. World J Surg Oncol (2014) 0.75

Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Med Res Methodol (2016) 0.75

Articles by these authors

Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry (1997) 41.93

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

Frequent overcrowding in U.S. emergency departments. Acad Emerg Med (2001) 5.08

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75

The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40

Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01

A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science (1991) 4.00

The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87

Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38

A semiparametric Bayesian approach to the random effects model. Biometrics (1998) 3.34

Sequence of the cloned gene for the constant region of murine gamma 2b immunoglobulin heavy chain. Science (1979) 3.21

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16

Telling the truth about terminal cancer. JAMA (1998) 3.07

Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A (1992) 3.01

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83

Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77

Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

A centimeter here, a centimeter there: does it matter? J Am Acad Dermatol (1995) 2.67

Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med (1998) 2.65

Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models. J Am Stat Assoc (2003) 2.59

K-SADS-PL. J Am Acad Child Adolesc Psychiatry (2000) 2.56

A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53

Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49

Birth of a relativistic outflow in the unusual γ-ray transient Swift J164449.3+573451. Nature (2011) 2.47

Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47

Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46

Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46

Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42

Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39

A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30

Dairy augmentation of total and central fat loss in obese subjects. Int J Obes (Lond) (2005) 2.30

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28

Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery (1978) 2.27

An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect (1990) 2.24

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Sustained growth and three-dimensional organization of primary mammary tumor epithelial cells embedded in collagen gels. Proc Natl Acad Sci U S A (1979) 2.15

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08

Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08

A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00

Maternal representations of attachment during pregnancy predict the organization of infant-mother attachment at one year of age. Child Dev (1991) 1.97

The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92

Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86

The relation of attachment status, psychiatric classification, and response to psychotherapy. J Consult Clin Psychol (1996) 1.81

A semi-parametric Bayesian approach to generalized linear mixed models. Stat Med (1998) 1.81

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80

Growth hormone secretion in children and adolescents at high risk for major depressive disorder. Arch Gen Psychiatry (2000) 1.78

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA (1992) 1.77

Rapid pathogen detection using a microchip PCR array instrument. Clin Chem (1998) 1.77

Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol (1995) 1.76

Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74

Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol Cell Biol (2001) 1.73

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71

Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71

Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67

The DSM-IV field trial for mixed anxiety-depression. Am J Psychiatry (1994) 1.66

Sustained growth in primary culture of normal mammary epithelial cells embedded in collagen gels. Proc Natl Acad Sci U S A (1980) 1.65

Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother (2006) 1.64

Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62

Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol (1994) 1.56

The cloning and sequence analysis of the aspC and tyrB genes from Escherichia coli K12. Comparison of the primary structures of the aspartate aminotransferase and aromatic aminotransferase of E. coli with those of the pig aspartate aminotransferase isoenzymes. Biochem J (1986) 1.55

The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54

Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. Stat Med (2001) 1.52

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Pulmonary responses to oil fly ash particles in the rat differ by virtue of their specific soluble metals. Toxicol Sci (1998) 1.50

Subsyndromal ("mixed") anxiety--depression in primary care. J Gen Intern Med (1994) 1.50

Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49

Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49

Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

On the Proteins of aa and aa Ephestia. Proc Natl Acad Sci U S A (1948) 1.46

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45

PCR detection of bacteria in seven minutes. Science (1999) 1.44

2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43

Study of cardiac rhythm in healthy newborn infants. Br Heart J (1980) 1.43

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43

Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42